Skip to content

Home
Leadership
Science
Data
Media
- News
- Videos
Partners
Contact

Contact

dna-slider-1124x124

Contact

Email Us

Partners:
partners@siwatherapeutics.com

Investors:
investors@siwatherapeutics.com

Media:
press@siwatherapeutics.com

About Us

SIWA’s 318H monoclonal antibody targets a biomarker on cancer cells and senescent cells. Our initial focus is on life-threatening cancers and related diseases with an unmet medical need (i.e., eligible for FDA Fast-tracking)

Recent News

New antibody shows strong potential against pancreatic cancer
SIWA Therapeutics, Inc. Presents New Data at the November 2022 American Association for Cancer Research Aging and Cancer Conference
SIWA Therapeutics Announces Promising Results in New Pancreatic Cancer Study

Navigation

Home
Leadership
Science
Data
Media
- News
- Videos
Partners
Contact